OSIRIS THERAPEUTICS, INC.

ADIPOGEN

chemical or biological agents which cause progenitor cells to be differentiated into fat tissue lineage cells for medical use;

ADIPONEXIN

chemical or biological agents which cause tissue-forming progenitor cells to commit into or produce differentiated adipose tissue in vitro or in vivo for medical use;

ADIPOPOIETIN

pharmaceuticals preparations for use in the partial or complete differentiation of mesenchymal progenitor cells or partially differentiated mesenchymal cells into the fat tissue lineage cells for medical use;

ALLOGEN

Allogeneic human mesenchymal stem cells for medical therapy namely, for use in conjunction with transplantation of tissues and solid organs;

ALLOSTEM

Allogeneic human mesenchymal stem cells for medical therapy namely, for use in conjunction with transplantation of tissues and solid organs;

ASTROSTEM

Cells for medical use, namely, for the treatment of neural injury and deficit;

CADENCE

Human allograft tissue;

CARDIOCEL

Pharmaceutical compositions, namely, mesenchymal stem cell (MSC) compositions for the regeneration of cardiac tissue and the treatment of heart disease.;

CARTIFORM

Cryopreserved biological human allograft tissue for subsequent implantation;

CHONDRIX

formulations of cartilage forming cells and a biodegradable matrix which form new cartilage tissue in vivo;

CHONDROGEN

chemical or biological agents which cause progenitor cells to differentiate into cartilage tissue lineage cells;

CHONDROGEN

Chemical or biological agents which cause progenitor cells to differentiate into cartilage tissue lineage cells;

CHONDROGEN

CHEMICAL OR BIOLOGICAL AGENTS WHICH CAUSE PROGENITOR CELLS TO DIFFERENTIATE INTO CARTILAGE TISSUE LINEAGE CELLS;

CHONDRONEXIN

chemical or biological agents for medical use which cause tissue-forming progenitor cells to commit into or produce differentiated cartilage tissue in vitro or in vivo;

CHONDROPOIETIN

chemical or biological agents which cause progenitor cells to differentiate into cartilage tissue lineage;

CHONDROPOIETIN

Chemical or biological agents which cause progenitor cells to differentiate into cartilage tissue lineage;

CHOREOCEL

Human allograft tissue;

CHRONDROPROGENIX

formulations of cartilage forming cells and a biodegradable matrix which form new cartilage tissue in vivo;

CHRONDROREGENIX

formulations of cartilage forming cells and a biodegradable matrix which form new cartilage tissue in vivo;

COLLAGEL

formulations of biodegradable materials combined with progenitor cells to form new tissue in vivo or in vitro for medical use;

CONNEXIN

chemical or biological agents for medical use which cause tissue-forming progenitor cells to proliferate in vitro or in vivo;

DERMAGEN

pharmaceutical preparations for use in the partial or complete differentiation of mesenchymal progenitor cells or partially differentiated mesenchymal cells into the dermis tissue lineage cells;

DERMAGEN

Pharmaceutical preparation for use in the partial or complete differentiation of mesenchymal progenitor cells or partially differentiation mesenchymal cells into the dermis tissue lineage cells;

DERMAGENIX

formulations of dermal-forming cells and biodegradable materials which form new dermis tissue in vivo;

DERMANEXIN

chemical or biological agents for medical use which cause tissue-forming progenitor cells to commit into or produce differentiated dermis tissue in vitro or in vivo;

DERMAPOIETIN

chemical or biological agents which cause progenitor cells to differentiate into dermis tissue lineage;

EPIDERMAGEN

formulations of epidermal and dermal forming cells and biodegradable materials which form new multi-layered skin in vitro or in vivo;

FABROGEN

Gene modified cells for the treatment of Fabry Disease;

GRAFIX

tissue-based wound care dressings;

GRAFIX PL

Tissue-based wound care dressings;

GRAFIX XC

Tissue-based wound care dressings;

GRAFIXPL

Tissue-based wound care dressings;

GRAFIXPL CORE

Tissue-based wound care dressings;

GRAFIXPL CORE

Tissue-based wound care dressings;

GRAFIXPL PRIME

Tissue-based wound care dressings;

MENVIVO

Medical knee implants comprised of living materials for healing and repairing meniscal tears and damage;

MESENKINES

chemicals, namely, cytokine growth factors produced by or with the aid of mesenchymal stem cells for medical diagnostic use;chemicals, namely, cytokine growth factors produced by or with the aid of mesenchymal stem cells for use in scientific and/or medical research;

MESENZYME

pharmaceutical preparations, namely, genetically engineered mesenchymal stem cells for the secretion of enzymes;MES ENZYME;

MESENZYME

PHARMACEUTICAL PREPARATIONS, NAMELY, GENETICALLY ENGINEERED MESENCHYMAL STEM CELLS FOR THE SECRETION OF ENZYMES;

MS-SCADS

MS SCADS;scientific research relating to cell testing to determine cell properties, namely, mass spectrometer analysis of cells for use in pharmaceutical product development;

MYOGEN

chemical or biological agents which cause progenitor cells to differentiate into muscle tissue;

MYONEXIN

chemical or biological agents for medical use which cause tissue-forming progenitor cells to commit into or produce differentiated muscle tissue in vitro or in vivo;

MYOPOIETIN

chemical or biological agents which cause progenitor cells to differentiate into muscle tissue lineage;

MYOPROGENIX

formulations of muscle forming cells and biodegradable materials which form new muscle tissue in vivo;

MYOREGENIX

formulations of muscle forming cells and biodegradable materials which form new muscle tissue in vivo;

NEURORESTORATIVE THERAPY

MESENCHYMAL STEM CELLS AND CELLS AND TISSUES DIFFERENTIATED THEREFROM FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS;

OSIRIS

Cells for medical use for regeneration of human tissue, namely, bone, cartilage, marrow, muscle, adipose, tissue, and tendon;Research and development for pharmaceutical products, namely, screening and genetic engineering of cell therapy products;

OSTEODX

chemical or biological agents for diagnosing the status of bone forming cells;

OSTEOGEN

chemical or biological agents which lead to partial or complete differentiation of mesenchymal progenitor cells or partially differentiated mesenchymal cells into the bone tissue lineage cells;

OSTEONEXIN

chemical or biological agents for medical use which cause tissue-forming progenitor cells to commit into or produce differentiated bone tissue in vitro or in vivo;

OSTEOPOIETIN

chemical or biological agents which cause progenitor cells to differentiate into bone tissue lineage;

OSTEOPROGENIX

formulations of bone forming cells and biodegradable materials which form new bone tissue in vivo;

OSTEOREGENIX

formulations of bone forming cells and biodegradable materials which form new bone tissue in vivo;

OVATION

Human allograft tissue;

OVATION

Human allograft tissue;

OVATIONOS

Human allograft tissue;OVATION OS;

PRESTIGE

Lyopreservation of human tissue;Processing of human tissue with viable cells for medical purposes;

PRESTIGE LYOPROCESSING

Lyopreservation of human tissue;Processing of human tissue with viable cells for medical purposes;

PRESTIGE LYOTECHNOLOGY

Lyopreservation of human tissue;PRESTIGE LYO TECHNOLOGY; PRESTIGE LYOPHILIZATION TECHNOLOGY;Processing of human tissue with viable cells for medical purposes;

PROGENIX

chemical or biological agents which cause tissue-forming progenitor cells to proliferate in vitro or in vivo for medical use;

PROMESYN

chemical or biological agents for medical use which cause tissue-forming progenitor cells to proliferate in vitro or in vivo;

PROSTERNIX

chemical or biological agents for medical use which cause tissue-forming progenitor cells to proliferate in vitro or in vivo;

QUARTET

Human allograft tissue;

REGENERATIVE MEDICINE

Stem Cell Processing Services;

REGENERATIVE MEDICINE

MESENCHYMAL STEM CELLS;

REGENERATIVE TISSUE THERAPY

human mesenchymal cell-containing products, namely cell or tissue preparations for culture or in vivo implantation;

REGENERATIVE TISSUE THERAPY

cell culturing for cancer or orthopaedic treatment;

RIGHT NOW

Chemical or biological agents which cause progenitor cells to differentiate into cartilage tissue lineage cells or which cause progenitor cells to differentiate into bone marrow stroma tissue lineage cells; pharmaceutical compositions, namely, mesenchymal stem cell (MSC) compositions for the regeneration of cardiac tissue and the treatment of heart disease; pharmaceutical compositions containing mesenchymal stem cells and their bone lineage committed descendants which may be combined with a matrix for bone repair and regeneration; cells for medical use for regeneration of human tissue, namely, bone, cartilage, marrow, muscle, adipose, tissue, and tendon composition; pharmaceutical composition containing mesenchymal stem cells which may be administered intravenously for immune response modulation and to affect tissue repair in treating immune and inflammatory disease;

SMART MEDICINE

Chemical or biological agents which cause progenitor cells to differentiate into cartilage tissue lineage cells or which cause progenitor cells to differentiate into bone marrow stroma tissue lineage cells, for medical use; pharmaceutical compositions, namely, mesenchymal stem cell (MSC) compositions for the regeneration of cardiac tissue and the treatment of heart disease; pharmaceutical compositions containing mesenchymal stem cells and their bone lineage committed descendants which may be combined with a matrix for bone repair and regeneration; cells for medical use for regeneration of human tissue, namely, bone, cartilage, marrow, muscle, adipose, tissue, and tendon composition; pharmaceutical composition containing mesenchymal stem cells which may be administered intravenously for immune response modulation and to affect tissue repair in treating immune and inflammatory disease;

STEM BANK

archiving services, namely, electronic storage and retrieval of biological data, physical storage and retrieval of biomedical research and biological materials;STEM BANK;BANK;biological research and testing; and tissue bank services featuring biological materials;

STEMBANK

Archiving services, namely, electronic storage and retrieval of biological data, physical storage and retrieval of biomedical research and biological materials;STEM BANK;Biological research and testing; and tissue bank services featuring biological materials;

STEMSCREEN

STEM SCREEN;MEDICAL SERVICE NAMELY, SCREENING ASSAYS FOR STEM CELLS;

STRAVIX

tissue-based wound care dressings;

STRAVIX

Cryopreserved human placental tissue allograft;

STRAVIX PL

Tissue-based wound care dressings;

STROMAGEN

chemical or biological agents which cause progenitor cells to differentiate cells into bone marrow stroma tissue lineage cells;

STROMAGEN

Chemical or biological agents which cause progenitor cells to differentiate cells into bone marrow stroma tissue lineage cells;

STROMAGENIX

formulations of stromal forming cells and a biodegradable materials which form new stromal tissue in vivo;

STROMANEXIN

chemical or biological agents for medical use which cause tissue-forming progenitor cells to commit into or produce differentiated stroma tissue in vitro or in vivo;

STROMAPOIETIN

chemical or biological agents which cause progenitor cells to differentiate into bone marrow stroma tissue lineage;

SUPPRESSIN

MESENCHYMAL STEM CELLS;SUPPRESSION;

TACTIX

tissue-based wound care dressings;TACTICS;

TENDANEXIN

chemical or biological agents for medical use which cause tissue-forming progenitor cells to commit into or produce differentiated tendon tissue in vitro or in vivo;

TENDOGEN

chemical or biological agents which cause progenitor cells to differentiate into tendon tissue lineage cells;

TENDOGENIX

formulations of tendon forming cells and biodegradable materials which form new tendon tissue in vivo for medical use;

TENDOPOIETIN

chemical or biological agents which cause progenitor cells to differentiate into tendon tissue lineage;

TRUSKIN

tissue-based skin allograft;

TRUSKIN

TRUE SKIN;tissue-based skin allograft;